9 June 2020
The European Medicines Agency (EMA) is set to review under a reduced timeline Gilead Sciences’ application for conditional marketing authorisation (CMA) of remdesivir to treat Covid-19. This short timeframe is said to be possible as the agency had already reviewed some data during the first cycle of the rolling review.
Go deeper with GlobalData
Japan-based Daiichi Sankyo has signed a basic agreement with the University of Tokyo, Nichi-Iko Pharmaceutical and RIKEN for the research and development of an inhalation formulation of Nafamostat to treat Covid-19. Nafamostat is an injectable therapy indicated in Japan to treat acute pancreatitis and disseminated intravascular coagulation.
India-based Bharat Serums and Vaccines (BSVL) has secured regulatory approval to assess its sepsis drug, Ulinastatin, in Phase III clinical trial to treat Covid-19. The trial, set to commence soon, will involve approximately 120 patients with mild to moderate symptoms of acute respiratory distress syndrome (ARDS).
SiO2 Materials Science has secured $143m contract from U.S. Government to speed-up the production scale-up of its primary packaging platform to store Covid-19 vaccines and therapeutics. SiO2’s product comprises a plastic container with a microscopic glass coating for biological drugs and vaccines.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
